Published August 2, 2026
The first federal bellwether trial involving Enfamil went to trial on July 6, 2026, brought by a father whose son, Daniel, died just days after birth. The case is widely viewed as a pivotal early test of how juries will respond to the scientific evidence behind claims that cow's milk-based infant formula significantly increases the risk of necrotizing enterocolitis (NEC) in premature infants.
The trial is playing out in the same federal multidistrict litigation (MDL 3026, Northern District of Illinois) that has already produced substantial verdicts against Similac maker Abbott, including a $70 million judgment in April 2026. This is the first bellwether case to test the evidence specifically against Mead Johnson/Reckitt, the maker of Enfamil, rather than Abbott.
A second bellwether trial — this one involving Similac claims brought by a California family whose premature daughter suffered permanent injuries rather than died — is scheduled to begin August 10, 2026. Running an Enfamil case and a Similac case as consecutive bellwethers lets both sides test how juries respond to claims against each manufacturer, and to both fatal and non-fatal NEC outcomes, before larger settlement negotiations take shape.
Not every recent development has favored plaintiffs: the Seventh Circuit Court of Appeals recently declined to revive a separate failure-to-warn claim against Abbott brought by a plaintiff named Ericka Mar, affirming a lower court's summary judgment win for the company. That ruling is a reminder that these cases don't all resolve the same way, and that the strength of an individual claim still depends heavily on its specific facts and expert evidence.
As of mid-2026, roughly 810 NEC baby formula cases remain pending in the federal MDL, and new cases continue to be filed. See Atumio's NEC baby formula case page for a free eligibility review, or start your case review directly.